FI101538B1 - Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-metyyli-1-piperatsinyyli)-10H-tieno[2,3-b][1,5]bentsodiatsepiinijohdannaisten valmistamiseksi - Google Patents

Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-metyyli-1-piperatsinyyli)-10H-tieno[2,3-b][1,5]bentsodiatsepiinijohdannaisten valmistamiseksi

Info

Publication number
FI101538B1
FI101538B1 FI932445A FI932445A FI101538B1 FI 101538 B1 FI101538 B1 FI 101538B1 FI 932445 A FI932445 A FI 932445A FI 932445 A FI932445 A FI 932445A FI 101538 B1 FI101538 B1 FI 101538B1
Authority
FI
Finland
Prior art keywords
methyl
thieno
piperazinyl
preparation
therapeutically useful
Prior art date
Application number
FI932445A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI932445A0 (fi
FI932445A (fi
FI101538B (fi
Inventor
John Fairhurst
Terrence Michael Hotten
David Edward Tupper
Original Assignee
Lilly Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB929211379A external-priority patent/GB9211379D0/en
Priority claimed from GB939309025A external-priority patent/GB9309025D0/en
Application filed by Lilly Industries Ltd filed Critical Lilly Industries Ltd
Publication of FI932445A0 publication Critical patent/FI932445A0/fi
Publication of FI932445A publication Critical patent/FI932445A/fi
Application granted granted Critical
Publication of FI101538B1 publication Critical patent/FI101538B1/fi
Publication of FI101538B publication Critical patent/FI101538B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI932445A 1992-05-29 1993-05-28 Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-mety yli-1-piperatsinyyli)-10H-tieno£2,3-b|£1,5|bentsodiatsepiinijohdannais ten valmistamiseksi FI101538B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211379A GB9211379D0 (en) 1992-05-29 1992-05-29 Pharmaceutical compounds
GB939309025A GB9309025D0 (en) 1993-04-30 1993-04-30 Pharmaceutical compounds

Publications (4)

Publication Number Publication Date
FI932445A0 FI932445A0 (fi) 1993-05-28
FI932445A FI932445A (fi) 1993-11-30
FI101538B1 true FI101538B1 (fi) 1998-07-15
FI101538B FI101538B (fi) 1998-07-15

Family

ID=26300951

Family Applications (1)

Application Number Title Priority Date Filing Date
FI932445A FI101538B (fi) 1992-05-29 1993-05-28 Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-mety yli-1-piperatsinyyli)-10H-tieno£2,3-b|£1,5|bentsodiatsepiinijohdannais ten valmistamiseksi

Country Status (21)

Country Link
EP (1) EP0582368B1 (ja)
JP (1) JP3219541B2 (ja)
CN (1) CN1043994C (ja)
AT (1) ATE198891T1 (ja)
AU (1) AU668159B2 (ja)
CA (1) CA2097016A1 (ja)
CZ (1) CZ282783B6 (ja)
DE (1) DE69329887T2 (ja)
DK (1) DK0582368T3 (ja)
ES (1) ES2153373T3 (ja)
FI (1) FI101538B (ja)
GR (1) GR3035587T3 (ja)
HU (1) HU218278B (ja)
IL (1) IL105827A (ja)
MX (1) MX9303124A (ja)
MY (1) MY109943A (ja)
NO (1) NO305125B1 (ja)
NZ (1) NZ247703A (ja)
PT (1) PT582368E (ja)
RU (1) RU2125574C1 (ja)
TW (1) TW268005B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457101A (en) * 1994-06-03 1995-10-10 Eli Lilly And Company Thieno[1,5]benzoidiazepine use
US5574028A (en) * 1994-10-31 1996-11-12 Eli Lilly And Company Method for treating anxiety
EG24221A (en) * 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
CR5278A (es) * 1995-03-24 1996-07-04 Lilly Co Eli Formulacion oral de 2-metil-tieno-benzodiacepina
EG23659A (en) * 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
US5891461A (en) * 1995-09-14 1999-04-06 Cygnus, Inc. Transdermal administration of olanzapine
WO1997035582A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating migraine pain
JP2000507945A (ja) * 1996-03-25 2000-06-27 イーライ・リリー・アンド・カンパニー 痛みを処置する方法
WO1997035583A1 (en) * 1996-03-25 1997-10-02 Eli Lilly And Company Method for treating pain
ZA978515B (en) * 1996-09-23 1999-03-23 Lilly Co Eli Intermediates and process for preparing olanzapine
CA2266444C (en) * 1996-09-23 2007-01-09 Eli Lilly And Company Olanzapine dihydrate d
ID21762A (id) * 1996-09-24 1999-07-22 Lilly Co Eli Formulasi partikel bersaput
AU2013305970B2 (en) 2012-08-21 2017-08-17 Saladax Biomedical Inc. Antibodies to aripiprazole haptens and use thereof
ES2669565T3 (es) 2012-08-21 2018-05-28 Janssen Pharmaceutica Nv Haptenos de risperidona y paliperidona
JP6216926B2 (ja) 2012-08-21 2017-10-25 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンに対する抗体及びその使用
CA2882597C (en) 2012-08-21 2020-04-14 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine haptens and use thereof
CA2882563C (en) 2012-08-21 2022-11-29 Eric Hryhorenko Antibodies to risperidone haptens and use thereof
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
PL2888234T3 (pl) 2012-08-21 2018-07-31 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
JP2015527365A (ja) 2012-08-21 2015-09-17 オルソ−クリニカル ダイアグノスティクス，インコーポレイティド パリペリドンに対する抗体及びその使用
CN104837838A (zh) 2012-08-21 2015-08-12 詹森药业有限公司 帕潘立酮半抗原
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
AU2013305895B2 (en) 2012-08-21 2017-10-19 Saladax Biomedical Inc. Antibodies to olanzapine haptens and use thereof
EP2888257B1 (en) 2012-08-21 2017-08-02 Janssen Pharmaceutica NV Haptens of quetiapine for use in immunoassays
EP3933406A3 (en) 2012-08-21 2022-04-20 Janssen Pharmaceutica NV Antibodies to risperidone and use thereof
WO2014031603A1 (en) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Antibodies to paliperidone haptens and use thereof
TR201816378T4 (tr) * 2012-08-21 2018-11-21 Janssen Pharmaceutica Nv Olanzapin haptenleri.
US10444250B2 (en) 2015-12-17 2019-10-15 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
JP6994461B2 (ja) 2015-12-17 2022-02-04 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンに対する抗体及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU629879A3 (ru) * 1974-11-26 1978-10-25 Лилли Индастриз Лимитед, (Фирма) Способ получени тиено(1,5) бензодиазепинов или их солей
DE2641378A1 (de) * 1975-09-24 1977-04-07 Sandoz Ag Neue organische verbindungen, ihre verwendung und herstellung
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
FI932445A0 (fi) 1993-05-28
CA2097016A1 (en) 1993-11-30
NO931917L (no) 1993-11-30
HU218278B (en) 2000-07-28
NZ247703A (en) 1995-07-26
HUT66180A (en) 1994-09-28
MX9303124A (es) 1993-11-01
DK0582368T3 (da) 2001-02-05
ES2153373T3 (es) 2001-03-01
HU9301579D0 (en) 1993-09-28
FI932445A (fi) 1993-11-30
EP0582368B1 (en) 2001-01-24
TW268005B (ja) 1996-01-11
DE69329887T2 (de) 2001-05-23
GR3035587T3 (en) 2001-06-29
EP0582368A1 (en) 1994-02-09
CN1085903A (zh) 1994-04-27
JP3219541B2 (ja) 2001-10-15
AU668159B2 (en) 1996-04-26
ATE198891T1 (de) 2001-02-15
CZ102493A3 (en) 1993-12-15
NO305125B1 (no) 1999-04-06
RU2125574C1 (ru) 1999-01-27
CN1043994C (zh) 1999-07-07
JPH0687862A (ja) 1994-03-29
PT582368E (pt) 2001-05-31
CZ282783B6 (cs) 1997-10-15
MY109943A (en) 1997-10-31
DE69329887D1 (de) 2001-03-01
NO931917D0 (no) 1993-05-26
IL105827A0 (en) 1993-09-22
FI101538B (fi) 1998-07-15
IL105827A (en) 1997-02-18
AU3980793A (en) 1993-12-02

Similar Documents

Publication Publication Date Title
FI101538B1 (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten 2-metyyli-4-(4-metyyli-1-piperatsinyyli)-10H-tieno[2,3-b][1,5]bentsodiatsepiinijohdannaisten valmistamiseksi
KR910018387A (ko) 약제학적 화합물
FI91258C (fi) Menetelmä lääkeaineina käyttökelpoisten 2-(heterosyklyylitio)karbapeneemijohdannaisten valmistamiseksi
HU906402D0 (en) Process for producing tricyclic carbapeneme derivatives an pharmaceutical preparatives containing these compounds as active substance
SE9703205L (sv) Ny kristallform av 2-metyl-4-(4-metyl-1-piperazinyl)-10H-tieno (2,3-b) (1,5)bensodiazepin och framställning därav
EP0255908A3 (en) 7-ûû3-(aminomethyl)-3-alkyl¨-1-pyrrolidinyl¨-quinoline-carboxylic acid-derivatives and pharmaceutical compositions containing them
AU7124391A (en) Condensed thiazole compounds, their production and use
AU636351B2 (en) N-heteroaryl-purin-6-amines, a process for their preparation and their use as medicaments
HUT55397A (en) Process for producing mevalonic acid derivatives comprising thienopyridine ring and pharmaceutical compositions containing such active ingredient
FI102178B (fi) Menetelmä terapeuttisesti käyttökelpoisten 1,2,3,3a,8,8a-heksahydro-1, 3a,8-trimetyylipyrrolo£2,3-b|indol-5-yylijohdannaisten valmistamiseksi
AU630575B2 (en) Benzodiazepine derivatives
ES2051996T3 (es) Producto farmaceutico.
FI103885B1 (fi) Menetelmä terapeuttisesti aktiivisten 1-bentsyyli-4-fenyylipiperatsiinijohdannaisten valmistamiseksi ja välituotteina käyttökelpoisia yhdisteitä
FR2639944B1 (fr) Nouveaux derives de l'indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU657423B2 (en) Novel piperidine derivatives and process for preparation thereof
FI104078B (fi) Menetelmä terapeuttisesti käyttökelpoisten (3-(1-piperatsinyyli)tieno£2,3-b|- ja -£2,3-c|pyridiinijohdannaisten valmistamiseksi
CA2112980A1 (fr) Procede de preparation de l'isomere dextrogyre d'un derive de l'isoindolinone
KR937000511A (ko) 신규한 화합물
JO1870B1 (en) CO2 derivatives - pyridinyl benzimidazole innovative